(2S,5R)-2,5-Dimethyl-pyrrolidine-1-carboxylic acid tert-butyl ester | 92012-42-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S,5R)-2,5-Dimethyl-pyrrolidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (2R,5S)-2,5-dimethylpyrrolidine-1-carboxylate
• CAS: 92012-42-5
• 化学式: C₁₁H₂₁NO₂
• 分子量: 199.293
• InChiKey: FZSBLLYQAULJDU-DTORHVGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2S,5R)-2,5-Dimethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 在 盐酸 作用下， 反应 2.5h， 生成 顺式-2,5-二甲基吡咯烷
  参考文献：
  名称：

  Catalytic hydrogenation of pyrroles at atmospheric pressure

  摘要：

  DOI：

  10.1021/jo00196a020
• 作为产物：
  描述：

  2,5-二甲基吡咯 在 platinum on activated charcoal potassium tert-butylate 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 97.5h， 生成 (2S,5R)-2,5-Dimethyl-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Catalytic hydrogenation of pyrroles at atmospheric pressure

  摘要：

  DOI：

  10.1021/jo00196a020

文献信息

• [EN] N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'AMINE N-ACYLE CYCLIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011111875A1

  公开（公告）日：2011-09-15

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, -C(O)-, etc.; W2 is C1- alkylene; W3 is a single bond, methylene, -NH-, -CR4=CR5-, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了一种化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，同时减少了传统的副作用风险，并对与精神分裂症以外的认知功能障碍相关的中枢神经系统疾病具有显著效果。提供了式（1）的N-酰基环胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4=CR5-等；环Q是式（a）的一组，其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a、R1b和R1c分别是相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药用可接受盐。
• PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
  申请人：Siddiqui M. Arshad

  公开号：US20120322791A1

  公开（公告）日：2012-12-20

  The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R 3 , R 6 , R 7 , R 8 , and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

  本发明提供了式（I）的吡唑吡咯啉化合物：其中L、T、Z、U、V、W、R3、R6、R7、R8和m如本文所定义，并且这些吡唑吡咯啉化合物的药物可接受的盐。这些吡唑吡咯啉化合物在治疗癌症和其他mTOR失调的疾病或疾病中具有用处。
• Complex Induced Proximity Effects: Enantioselective Syntheses Based on Asymmetric Deprotonations of N-Boc-pyrrolidines
  作者：Peter Beak、Shawn T. Kerrick、Shengde Wu、Jingxi Chu

  DOI：10.1021/ja00087a008

  日期：1994.4

  Lithiation of N-Boc-pyrrolidine (6) with sec-butyllithium (s-BuLi)/(-)-sparteine (14) effects an asymmetric deprotonation to give (S)-2-lithio-N-Boc-pyrrolidine ((S)-22),which reacts with electrophiles to provide the 2-substituted N-Boc-pyrrolidines 7-11 and 13 in enantiomeric excesses which generally are >90%. In the lithiation-silylation of 6 the chiral ligand 15 gives 7 with a lower enantiomeric excess and chiral ligands 16 and 17 give 7 with lower and opposite enantiomeric excesses than that obtained with 14. Diastereoselective amplification operates in a sequential lithiation-substitution sequence to provide the conversion of (S)-2-methyl-N-Boc-pyrrolidine ((S)-10) of 95% enantiomeric excess with s-BuLi/14 to (S,S)-2,5-dimethyl-N-Boc-pyrrolidine ((S,S)-19) with >99% enantiomeric excess. Synthetic preparations of a useful chiral ligand, (R)-alpha,alpha-diphenyl-2-pyrrolidine ((R)-20), and a useful chiral auxiliary, (S,S)2,5-dimethylpyrrolidine hydrochloride ((S,S)-21), are reported. Reactions of racemic and enantioenriched 2-lithio-N-Boc-pyrrolidine and investigation of sequential lithiations-deuterations of 6 establish the reaction pathway to be asymmetric deprotonation rather than asymmetric substitution. A rationalization for the enantioselective deprotonation is provided.
• KAISER, H. -P.;MUCHOWSKI, J. M., J. ORG. CHEM., 1984, 49, N 22, 4203-4209
  作者：KAISER, H. -P.、MUCHOWSKI, J. M.

  DOI：——

  日期：——
• PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS
  申请人：Bristol-Myers Squibb Holdings Ireland

  公开号：EP2499115B1

  公开（公告）日：2016-07-27